Latest News


Mini simpozij infrastrukturnih centrov

Mini simpozij infrastrukturnih centrov Medicinske fakultete Univerze v Ljubljani, bo potekal 21. junija 2018 med 14:00 in 17:00 v srednji predavalnici na Medicinski fakulteti Univerze v Ljubljani na Korytkovi 2.

Taste of Genomics

Taste of Genomics: the 70th anniversary of Prof. Radovan Komel and 13th CFGBC Scientific Symposium will take place from June 20th-21st 2018 at the University of Ljubljana, Faculty of Medicine, Slovenia.

Systems Medicine Conference in Slovenia

Systems Medicine Conference in Slovenia: National Awareness Event,12th CFGBC Symposium and “Systems Medicine” Workshop took place from June 8th-9th 2017 at Hotel Slon, Ljubljana, Slovenia.


Systems Medicine for mechanistic disease redefinition and omics-based drug repurposing for rapid proof of concept and patient relevant impact

Harald Schmidt1

1Dept of Pharmacology and Personalised Medicine, Maastricht University, Maastricht, the Netherlands

Drug discovery and development has not only long development time, its expenses have been increase exponentially and the success rate is decreasing. As a result, the average cost for a market entry of a drug in the U.S.A. reached 3.8 billion USD. Obviously, this is neither sustainable for the pharmaceutical industry but also the health care providers and tax payers who indirectly need to refinance these costs. Moreover, the low success rate yields stagnation in medical innovation and patient benefit from basic research pushing the entire biomedical translational drug R&D process in a deep crisis. Systems Medicine can address this efficacy challenge by redefining diseases by mechanisms rather t5han symptoms and organs and thereby allowing mechanism-based drug discovery and rapid repurposing. By repurposing a registered (set of) drug(s) for a new indication, nearly the complete lead optimisation and most or all of clinical phase I is eliminated. Ideally, immediate phase II clinical trialling is ethically possible and medically justified, provided solid pre-clinical evidence on the target and drug can be provided. Compared to having to start from lead discovery, the net gain in time is at least 9 years in average. Depending on the indication (acute or chronic) and resulting trial length the gain may be even more. 

2006 - University of Ljubljana, Faculty of Medicine, Center for Functional Genomics and Bio-chips.